ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023
2023年7月7日 - 5:45AM
ビジネスワイヤ(英語)
All stockholders of record as of May 12,
2023 who have not yet voted are encouraged to vote
ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a
pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today
announced its 2023 Annual Meeting of Stockholders (the “Annual
Meeting”), which was scheduled to be held this morning, was
convened and adjourned, without any business being conducted, due
to the lack of the required quorum.
As a result of the required quorum not being present, the Annual
Meeting has been adjourned to 10:00 am, Eastern Time on Tuesday,
July 25, 2023 (“Adjourned Annual Meeting”) to allow additional time
for the Company’s stockholders to vote on the proposals set forth
in the Company’s definitive proxy statement filed with the United
States Securities and Exchange Commission (“SEC”) on May 24, 2023,
and thereby satisfy the required quorum for the meeting. The
Adjourned Annual Meeting will be conducted via a live webcast.
During the current adjournment period, the Company will continue
to solicit votes from its stockholders with respect to the
proposals set forth in the Company’s proxy statement.
Only stockholders of record as of the record date, May 12, 2023,
are entitled to vote. Valid proxies previously submitted in respect
of the Annual Meeting will be voted at the Adjourned Annual Meeting
unless properly revoked, and stockholders who have previously
submitted a valid proxy card or otherwise voted need not take any
action unless they wish to change their vote.
The Company encourages all stockholders of record as of May 12,
2023 who have not yet voted, to do so.
Stockholders who have any questions or require any assistance
with how to complete a proxy or who do not have the required
materials, may call the technical support number that will be
posted on the Virtual Shareholder Meeting log in page.
Important Information
This material may be deemed to be solicitation material in
respect of the Annual Meeting to be held on July 25, 2023. As
discussed in the press release filed as an exhibit to this filing,
the Company previously filed a definitive proxy statement with the
SEC on May 24, 2023. BEFORE MAKING ANY VOTING DECISIONS, SECURITY
HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY
OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN
IMPORTANT INFORMATION ABOUT THE ADJOURNED MEETING. The definitive
proxy statement has been mailed to stockholders who are entitled to
vote at the Annual Meeting. No changes have been made in the
proposals to be voted on by stockholders at the Annual Meeting. The
Company’s proxy statement and any other materials filed by the
Company with the SEC can be obtained free of charge at the SEC’s
website at
https://www.sec.gov/Archives/edgar/data/1681682/000165495423007157/ndra_def14a.htm.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
the more than 700,000 ultrasound systems in use globally today.
TAEUS® is initially focused on the measurement of fat in the liver
as a means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver
conditions that affect over two billion people globally, and for
which there are no practical diagnostic tools. Beyond the liver,
ENDRA is exploring several other clinical applications of TAEUS®,
including visualization of tissue temperature during energy-based
surgical procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” “anticipate,” “attempt,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“hope,” “intend,” “may,” “plan,” “possible,” “potential,”
“project,” “seek,” “should,” “will,” “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches;
statements relating to future financial position and projected
costs and revenue; expectations concerning ENDRA’s business
strategy; and statements regarding ENDRA’s ability to find and
maintain development partners. Forward-looking statements involve
inherent risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements as a
result of various factors including, among others: the ability to
raise additional capital in order to continue as a going concern;
the ability to obtain regulatory approvals necessary to sell ENDRA
medical devices in certain markets in a timely manner, or at all;
the ability to develop a commercially feasible technology and its
dependence on third parties to design and manufacture its products;
the impact of COVID-19 on ENDRA’s business plans; the ability to
find and maintain development partners; market acceptance of
ENDRA’s technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the SEC. You should not rely upon forward-looking
statements as predictions of future events. The forward-looking
statements made in this press release speak only as of the date of
issuance, and ENDRA assumes no obligation to update any such
forward-looking statements to reflect actual results or changes in
expectations, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230706666281/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com Investor
Relations Contact: Yvonne Briggs LHA Investor Relations (310)
691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 4 2024 まで 5 2024
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 5 2023 まで 5 2024